Dr. David Samadi Reveals Some Truths About Prostate Cancer And Its Possible Treatments

Mitt Romney, recently disclosed that he had prostate surgery last year on a tumor that was slowly growing before it was taken care of. It is likely that he did so because he plans on running for the United States Senate in Utah once the seat is vacated. Dr. David Samadi revealed that Dr. Thomas Ahlering from UC Irvine Hospital completed the surgery, and he also revealed that Mitt is in good shape now. In 2017 there were more than 161,000 men who were diagnosed with prostate cancer, and in 2018 it is expected that there will be over 164,000 men diagnosed with the disease. It is unique for men under the age of 40 to get prostate cancer, but 60% of men over the age of 65 do.

Mitt Romney was 70 years old when he was diagnosed with prostate cancer, but he isn’t the only politician to come out of prostate cancer surgery with good news. Colin Powell, in 2003, had his prostate gland removed, and John Kerry, during his presidential run, also underwent surgery for prostate cancer and never had any issues after. The truth is, there are two options for a man to consider once he has been diagnosed with prostate cancer, and Dr. David Samadi has commented on the fact that he always goes over these options with his patients, which are radiation treatment or surgery. If the prostate cancer has not spread beyond itself, Dr. Samadi usually recommends his patients to get surgery.

Dr. David Samadi has talked about the reasons why he recommends surgery over radiation in most cases. One of these reasons is that men who receive radiation are two times as likely to die afterwards from the cancer and just a bit less likely to die earlier than men who had surgery. Exposure to radiation can also cause other kinds of cancer, and patients who first get radiation therapy have a much harder time being good candidates for surgery afterwards.

Dr. David Samadi is the Chief of Robotic Surgery and the Chairman of Urology at Lenox Hill Hospital. He was born in Iran but moved to Belgium, London, and then the United States after leaving the country during the Iranian Revolution. He studied at Stony Brook University in New York where he earned a degree in biochemistry and went on the receive his M.D. from New York’s S.U.N.Y., Stony Brook School of Medicine.

Learn More: www.huffingtonpost.com/author/dr-david-samadi

“Mikhail Blagosklonny: Restoring & Reguvinating The Health Of Multitudes!”

Mikhail Blagosklonny is one of the leading scientists fighting the war on cancer and anti-aging in the United States. His discoveries have been remarkable in regard to the drug he developed Rapamycin and the contributions he has made with compelling evidence of other cutting-edge scientific case studies that he has compiled into a website by the name Oncotarget. Oncotarget publishes papers and medical findings having to with oncology, pathology, immunology, microbiology, autophagy, chromosomes and cell demise. Oncotarget was founded in 2010 by Blagosklonny and Andrei V. Gudkov who are now the acting editors and chief. Both men are also professors at the same Roswell Park Cancer Institute. Oncotarget has become a well-used resource for many medical professionals when charting a course for patient treatment as it encompasses a very large and innovative archival of published documents having to deal with cancer and other aforementioned functions of the body. Its growing notoriety is in part by its astute, productive, prompt and peer-reviewed research papers and case files.

Rapamycin, known for its antifungal properties, was uncovered from Rapa Nui’s earthen soil. Rapa Nui, better known as Easter Island, lies off the Polynesian coast of Chile, on an island of the Pacific Ocean. It was discovered around 1987. Further investigation into the properties of Rapamycin concluded that it had a wide range of immunosuppressant qualities and as a result has made an excellent drug that assists the organs after transplant surgery. There has been remarkable success in the use of this macrolide compound for its ability to suppress the growth of cancer cells. The pharmaceutical has been cleared by the Food and Drug Administration and is currently being used alongside of corticosteroids and cyclosporine to counteract renal refutation. Some of the most current remedial treatments have shown very promising effects on the following conditions.

  • Therapy for treating the common Alzheimer’s disease in the elderly.
  • For augmented lifespan of a person/anti-aging properties
  • Remedy for Facial Fibroid tumor
  • Treatment of Tuberous Sclerosis Complex (benign tumors on body parts)
  • Overlaying of the Coronary Stent
  • Remedial cure of Sporadic Lymphangioleiomyomatosis (lung tumor)
  • Remedy for hemolytic-uremic syndrome (blood disease)
  • Curing of Muscular Dystrophy
  • Therapy for the skin disease, Systemic Lupus Erythematosus (inflammatory disease)

Dr. Blagosklonny has an extensive acumen in a vast array of fields but specializes in oncology, biometrics, cellular and molecular biology. He has written and published over 250 medical papers and is a regularly contributing author to many other publications, outside of Oncotarget. Mikhail is passionate about eradicating disease and thusly pain during a humans lifetime and continues his work along this matter for the betterment of health, science and humanity. After all, finding a promising cancer cure is no small feat!

Life Line Screening Great Achievements In Preventative HealthCare

Life Line Screening is an independently operated prevention and wellness company started in 1993 and situated in Austin, TX. The organization conducts society-based health screening services targeting adults in the entire USA. Life Line Screening is a spearheading supplier of community-based and direct-to-user preventive health screenings. A significant number of screenings done by the organization identify different health issues such as carotid artery disease, stroke, abdominal aortic aneurysm, and more, which usually show no symptoms. These are medical health care  problems; nonetheless, that can be forestalled if the risks are recognized early.

The organization was established in Florida by Timothy Phillips and Colin Scully, and since the time, the services extended over the USA and U K. By 1998, the organization covered most parts of the United States whereby it provided screenings to over 500,000 individuals. In 2007, the organization included finger-stick blood testing in its screenings for full cholesterol count (lipid panel), inflammation (C-reactive protein) and diabetes (glucose).

Life Line preventive wellbeing screening administrations were propelled in the United Kingdom in 2007. In 2008, a year later, screening services were enhanced to incorporate atrial fibrillation screenings and in 2012, the company started providing services in Australia utilizing the organization name “Screen for life”.

The objective of Life Line Screening is to ensure people get aware of unidentified health issues and motivate them to follow-up with their private physicians. The leading supplier of community-based preventive well-being screenings within the USA utilizes high-tech equipment similar with those found in hospitals. Also, screenings are conducted by well-trained professionals in healthcare and results are analyzed by board certified physicians who ensure the highest standards.

Life Line Screenings has joined forces with various insurance organizations over the globe, for utilizing their preventive well-being administrations which have covered benefits. Different health facilities widely use the organization’s services as a major aspect of their patient care. For instance, Life Line Screenings conducted over 290,000 vascular screenings between 2008 and 2012 according to the clinical research performed by Oxford University. The study added an expansive awareness making key improvements towards preventive well-being. Since its launching, the organization has conducted more than 8 million health screenings.

About Life Line Screenings: http://www.lifelinescreening.com/results